Skip to content
10-Q

Quarterly Report

CALYPTE BIOMEDICAL CORP

0001437749-12-000876

← back to feed
Filed
Jan 27, 2012 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2011 · Jan 27, 2012 547.83M sh
Stockholders Equity Q3 2011 · Sep 30, 2011 −$4.85M
Stockholders Equity Q3 2011 · Dec 31, 2010 −$5.09M
Current Liabilities Q3 2011 · Sep 30, 2011 $3.32M
Current Liabilities Q3 2011 · Dec 31, 2010 $3.89M
Total Liabilities Q3 2011 · Sep 30, 2011 $6.95M
Total Liabilities Q3 2011 · Dec 31, 2010 $7.43M
Current Assets Q3 2011 · Sep 30, 2011 $323K
Current Assets Q3 2011 · Dec 31, 2010 $403K
Total Assets Q3 2011 · Sep 30, 2011 $2.1M
Total Assets Q3 2011 · Dec 31, 2010 $2.33M
Shares Diluted Q3 2011 · Sep 30, 2010 492.57M sh
Shares Diluted Q3 2011 · Sep 30, 2010 478.87M sh
Capex Q3 2011 · Sep 30, 2010 $34K
Operating Cash Flow Q3 2011 · Sep 30, 2010 −$629K
Cash And Equivalents Q3 2011 · Sep 30, 2010 $31K
Cash And Equivalents Q3 2011 · Dec 31, 2009 $160K
Sga Expense Q3 2011 · Sep 30, 2010 $253K
Sga Expense Q3 2011 · Sep 30, 2010 $739K
Rd Expense Q3 2011 · Sep 30, 2010 $69K
Rd Expense Q3 2011 · Sep 30, 2010 $189K
Net Income Q3 2011 · Sep 30, 2010 $10.49M
Net Income Q3 2011 · Sep 30, 2010 $9.26M
Operating Income Q3 2011 · Sep 30, 2010 −$275K
Operating Income Q3 2011 · Sep 30, 2010 −$776K
Cost Of Revenue Q3 2011 · Sep 30, 2010 $77K
Cost Of Revenue Q3 2011 · Sep 30, 2010 $162K